Egetis Therapeutics Management
Management criteria checks 3/4
Egetis Therapeutics' CEO is Nicklas Westerholm, appointed in Jun 2017, has a tenure of 6.83 years. total yearly compensation is SEK5.90M, comprised of 47.5% salary and 52.5% bonuses, including company stock and options. directly owns 0.079% of the company’s shares, worth €114.30K. The average tenure of the management team and the board of directors is 6.8 years and 4.7 years respectively.
Key information
Nicklas Westerholm
Chief executive officer
kr5.9m
Total compensation
| CEO salary percentage | 47.5% |
| CEO tenure | 6.8yrs |
| CEO ownership | 0.08% |
| Management average tenure | 6.8yrs |
| Board average tenure | 4.7yrs |
Recent management updates
Recent updates
CEO Compensation Analysis
| Date | Total Compensation | Salary | Company Earnings |
|---|---|---|---|
| Dec 31 2023 | n/a | n/a | -kr327m |
| Sep 30 2023 | n/a | n/a | -kr319m |
| Jun 30 2023 | n/a | n/a | -kr286m |
| Mar 31 2023 | n/a | n/a | -kr240m |
| Dec 31 2022 | kr6m | kr3m | -kr194m |
| Sep 30 2022 | n/a | n/a | -kr148m |
| Jun 30 2022 | n/a | n/a | -kr113m |
| Mar 31 2022 | n/a | n/a | -kr114m |
| Dec 31 2021 | kr5m | kr3m | -kr104m |
| Sep 30 2021 | n/a | n/a | -kr147m |
| Jun 30 2021 | n/a | n/a | -kr153m |
| Mar 31 2021 | n/a | n/a | -kr155m |
| Dec 31 2020 | kr4m | kr2m | -kr178m |
| Sep 30 2020 | n/a | n/a | -kr127m |
| Jun 30 2020 | n/a | n/a | -kr134m |
| Mar 31 2020 | n/a | n/a | -kr127m |
| Dec 31 2019 | kr3m | kr2m | -kr61m |
| Sep 30 2019 | n/a | n/a | -kr61m |
| Jun 30 2019 | n/a | n/a | -kr48m |
| Mar 31 2019 | n/a | n/a | -kr46m |
| Dec 31 2018 | kr3m | kr2m | -kr85m |
| Sep 30 2018 | n/a | n/a | -kr95m |
| Jun 30 2018 | n/a | n/a | -kr103m |
| Mar 31 2018 | n/a | n/a | -kr91m |
| Dec 31 2017 | kr1m | kr1m | -kr88m |
Compensation vs Market: Nicklas's total compensation ($USD539.46K) is about average for companies of similar size in the German market ($USD678.96K).
Compensation vs Earnings: Nicklas's compensation has increased whilst the company is unprofitable.
CEO
Nicklas Westerholm (47 yo)
6.8yrs
Tenure
kr5,900,000
Compensation
Mr. Nicklas Westerholm has been the Chief Executive Officer of Egetis Therapeutics AB (publ) (formerly known as PledPharma AB (publ)) since June 16, 2017. Mr. Westerholm has been working in the AstraZeneca...
Leadership Team
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| Chief Executive Officer | 6.8yrs | kr5.90m | 0.079% SEK 114.3k | |
| Founder | 18.3yrs | no data | no data | |
| Founder | 18.3yrs | no data | no data | |
| Founder | 18.3yrs | no data | no data | |
| Founder | 18.3yrs | no data | no data | |
| Founder | 18.3yrs | no data | no data | |
| Chief Financial Officer | 2.8yrs | no data | 0.10% SEK 149.0k | |
| Vice President of Operations | 1.1yrs | no data | no data | |
| Chief Scientific Officer | no data | kr655.00k | no data | |
| Head of IR & Business Development | 2.2yrs | no data | no data | |
| General Counsel & Head of Compliance | less than a year | no data | no data | |
| Global Head of Marketing & Brand Strategy | 1.9yrs | no data | no data |
6.8yrs
Average Tenure
61yo
Average Age
Experienced Management: P0F's management team is seasoned and experienced (6.8 years average tenure).
Board Members
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| Member of Scientific Advisory Board | 5.8yrs | no data | no data | |
| Director | 3yrs | kr300.00k | 1.07% SEK 1.5m | |
| Independent Director | 1.3yrs | no data | no data | |
| Director | 3.5yrs | no data | no data | |
| Chairman of the Board | 3yrs | kr600.00k | 0.097% SEK 139.2k | |
| Independent Director | 7.3yrs | kr200.00k | 0.014% SEK 19.7k | |
| Independent Director | 7.3yrs | kr200.00k | 0.013% SEK 18.5k | |
| Member of Scientific Advisory Board | 5.8yrs | no data | no data | |
| Member of Scientific Advisory Board | no data | no data | no data |
4.7yrs
Average Tenure
61yo
Average Age
Experienced Board: P0F's board of directors are considered experienced (4.7 years average tenure).